Peritoneal InflammationNCT00642005
Humidification in Laparoscopic Colonic Surgery
A study testing Fisher and Paykel Humidifier (MR860) and Standard insufflation in people with Peritoneal Inflammation, run by University of Auckland, New Zealand at 3 sites in New Zealand.
Trial summary
Laparoscopic surgery allows surgeons to remove bowel via small incisions. To allow insertion of a camera and instruments, cold and dry gas is blown into the abdominal cavity. This project investigates the use of warmed, humidified gas in laparoscopic surgery. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Peritoneal Inflammation
- What is being tested?
- Fisher and Paykel Humidifier (MR860) and Standard insufflation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 82 participants
- Where
- 3 sitesNew Zealand
- Study dates
- Apr 2008to Aug 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- All patients 15 years and over undergoing elective laparoscopic colonic resection at all three auckland hospitals
Who cannot join
- Acute cases
- Stoma formation (preop or intraop decision)
- Decision to change to open surgery preoperatively (intraop conversions included as intention to treat)
- Rectal lesions defined as 15 cm from anal verge on imaging and/or sigmoidoscopy / colonoscopy
- Steroid dependence
- Inability to consent or answer SRS questions due to cognitive impairment or language barrier
- ASA >= 4
Trial locations and contacts
3 sites in 1 country.
New Zealand3 sites
Middlemore Hospital
Auckland, Otahuhu
Auckland City Hospital
Auckland
North Shore Hospital
Auckland
About this study
Official title: Humidification in Laparoscopic Colonic Surgery - A Double Blinded, Randomised Controlled Trial.
Laparoscopic surgery allows surgeons to remove bowel via small incisions. To allow insertion of a camera and instruments, cold and dry gas is blown into the abdominal cavity. This project investigates the use of warmed, humidified gas in laparoscopic surgery. The hypothesis is that this will result in less damage to internal surfaces, and shorten recovery time. Previous studies have demonstrated positive outcomes in laparoscopic gallbladder operations. The investigators plan to study patients undergoing laparoscopic colon operations, as these operations are longer and the effect of humidification will be magnified. The investigators will enroll 74 patients: 37 will have the operation with cold dry gas, and 37 will have warm, humidified gas. The investigators will measure intraoperative heat loss, postoperative pain, fatigue, nausea and vomiting, and time to return of bowel function.
Read the detailed description
The key determinants of a return to normal activity after major colorectal surgery are pain and fatigue. Our research group has an interest in enhancing perioperative care to reduce postoperative fatigue.
We have investigated the effect of peritoneal inflammation and the local production of cytokines on fatigue. Our data indicate that there is an association between the development of postoperative fatigue and the concentration of peritoneal cytokines following colorectal surgery. (Paddison, Hill - manuscript in submission). It is known that following surgery, there are two possible modes of communication between the cytokines and the brain. One is a hormonal routine by which the cytokines produced at the site of surgery enter the blood and proceed through cell surface receptors to act directly on the brain. The second method is a neural route represented by paracrine action of cytokines on primary afferent neurons that innervate the body site where the injury has taken place. In the abdominal cavity, the vagus nerve plays an important role in the latter form of communication. Vagal sensory neurons express large numbers of receptors for immune derived mediators, including a number of cytokines involved in inflammation and it has been shown that a major function of vagus may involve signaling immune and inflammatory situations. The vagus is unique as it has termination at the nucleus tractus solitarius (NTS) in the brain. The NTS is intensely activated following peripheral immune challenges and is also by far the most sensitive area in the brain following immune stimulation. The NTS projects monosynaptically to many regions of the brain which mediate sickness responses. Pro-inflammatory cytokines have been found in the blood, the skin, and the central nervous system after surgery and injury, however following major abdominal surgery such as colectomy these cytokines are found in very high concentrations in the peritoneal cavity. This local production of cytokines is far in excess of the amounts found in the serum suggesting an important local role and potentially a significant role in metabolic changes associated with colonic surgery. Therefore, inflammation and the consequent production of large concentrations of cytokines at the site of the surgery may activate the rich neurosensory vagal afferents to stimulate regions of the brain which mediate "sickness" responses. Therefore, it is feasible to hypothesize that strategies which lead to a reduction of the concentration of pro-inflammatory cytokines will lead to a reduction in post-operative fatigue.
In laparoscopic surgery, insufflated CO2 is delivered as defined by the United States Pharmacopoeia and National Formulary, which requires impurity of less than 200 parts per million, including water vapor. It is delivered at room temperature (21°C) with a relative humidity approaching 0%. Heat is lost by the body in warming and humidifying the cold, dry gas 1, and animal models have demonstrated that this can induce hypothermia. Initial human investigations showed that by simply heating the insufflating gas, core temperature was maintained and pain scores were improved. Additional findings showed heating and humidification helped to maintain core temperature in a porcine model 4. There is clinical evidence suggesting that heating and humidification can increase intraoperative core body temperature and reduce post-operative use of analgesia and pain scores for up to 14 days postoperatively. This intervention has also been linked significantly to an earlier return to normal activity in patients undergoing cholecystectomy.
Experimental studies have also shown that humidified gas is associated with less peritoneal and systemic inflammation compared to unhumidified gas. Furthermore, it has been demonstrated that use of warm, humidified gas is associated with a reduction in the concentration of peritoneal IL-6. The magnitude of this change is even larger than the effect seen after administration of anti-inflammatory agents in a similar setting. Significant reduction in other inflammatory peritoneal cytokines (TNF, IL-1) have also been observed in patients undergoing laparoscopic cholecystectomy with warmed CO2 insufflation gas.
Currently, there are no studies which have examined the effect of humidification in patients undergoing laparoscopic colonic surgery. We hypothesize that use of warm, humidified insufflation gas will lead to a reduction in hypothermia and concentration of peritoneal cytokines, with consequently decreased post-operative pain and fatigue, and earlier return to normal bowel function and activity. Our aim is to design and execute a double-blinded randomised controlled trial to test this hypothesis.
Research Design and Methods
Patients will be recruited from out-patient clinics across all three Auckland public hospitals. On the day of the operation, using opaque envelopes and computer generated random numbers; patients will be allocated into 2 groups. The intervention group will receive warm, humidified insufflation gas and control group will receive standard dry gas. Other intraoperative variables will be standardized and controlled. The patients, operating surgeons and other members of the clinical team will be blinded to the treatment given.
Using the data from a previous study measuring post-operative pain following colonic surgery; 37 patients are required in each group in to provide a 20% reduction in post-operative in hospital opiate use with alpha of 0.05 and power of 0.8. In order to achieve the required numbers we aim to enroll all patients undergoing laparoscopic colectomy from North Shore, Auckland and Middlemore Hospitals. Exclusion criteria:Patients under 15 years, acute cases, stoma formation (preop or intraop decision, decision to change to open surgery preoperatively (intraop conversions will be included as intention to treat), rectal lesions defined as less than 15cm from anal verge on imaging and/or sigmoidoscopy / colonoscopy, steroid dependence, inability to consent or answer SRS questions due to cognitive impairment or language barrier, ASA >= 4.
A reduction in postoperative morphine use forms the primary outcome of this study. Secondary outcomes include postoperative pain, fatigue, intraoperative heat loss and postoperative inflammatory response as measured by plasma and peritoneal pro-inflammatory cytokine concentration. Other outcomes that will be measured include nausea and vomiting, antiemetic use, and return of bowel function; with a reduction in these variables contributing to an endpoint of earlier return to normal activity.
Morphine equivalent analgesia usage will be documented in PACU, day of operation, day 1, day 2, and day 3. Visual analog scale measures of pain at rest will be obtained preoperatively, then at 2, 4, 8 and 12 hours, and days 1, 2, 3, 7, 14, 30, and 60 postoperatively.
Intraoperative temperature will be measured at 15min intervals using an naso-pharyngeal probe. A drain will be placed in the peritoneal cavity at the conclusion of surgery. On the morning following the operation, fluid from this drain as well as a simultaneous sample of blood will be collected, centrifuged and stored. Antioxidant levels will measures, and cytokine assays will be carried out by multiplexed cytometric bead immunoassays using the LINCOplex system (LINCO Research, St Charles, MO, USA). Drain fluid will be assayed for pro-inflammatory cytokines, IL-1a, TNF-a, IL-6, IL-8, IL-10 concentrations. Data will be acquired using a Luminex cytofluorimeter and analyzed using Luminex 100 IS software version 2.3 running a 4-parameter curve fit.
The SRS score will be used to measure surgical recovery, and will be administered preoperatively and also at days 1, 3, 7, 30, and 60. Anti-emetic use as well as time of return of normal bowel function (ability to eat and drink one complete hospital meal, passages of flatus or bowel motion and absence of nausea and vomiting) will also be recorded. Patients will be contacted on discharge to ascertain time to return of normal preoperative function.
- Conditions
- Peritoneal Inflammation
- Being tested
- Fisher and Paykel Humidifier (MR860), Standard insufflation
- Keywords
- Humidification, Laparoscopy, Colon, Hemicolectomy, Warming
- Medical subject headings
- Peritonitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fisher and Paykel Humidifier (MR860)Procedure or surgery
Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
Standard insufflationProcedure or surgery
No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Humidified and warmed carbon dioxide laparoscopic insufflation. Receives: Procedure: Fisher and Paykel Humidifier (MR860) |
| 2 | Placebo comparator | Cold and dry carbon dioxide laparoscopic insufflation. Receives: Procedure: Standard insufflation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain by visual analogue scale
Measured: preop, 2 hours, 4 hours, 8 hours, 12 hours, day 1, day 2, day 3, day 7, day 14, day 30, day 60
Morphine equivalent analgesia use
Measured: PACU, day of OT, day 1, day 2, day 3, total in hospital
Secondary outcomes (6)
Intraoperative temperature by esophageal probe
Measured: 15 min intervals during surgery
Plasma and peritoneal cytokine concentration
Measured: Morning of surgery
Antiemetic use
Measured: PACU, day of OT, day 1, day 2, day 3
Return of bowel function - passage of flatus, bm, and eating first meal
Measured: daily
Any complications
Measured: Up to 3 months postoperatively
Surgical recovery by SRS
Measured: preop, day 1, day 2, day 3, day 7, day 30, day 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2008 (estimated)
- Study startApr 2008
- Primary completionJun 2009
- Study completionAug 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Peritoneal InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Auckland, New Zealand
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Andrew G Hill, University of Auckland, New Zealand
- Investigators
- Andrew G Hill, MBChB, MD, FRACS, Study chair, University of Auckland, New Zealand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00642005
- Sponsor's protocol ID
- Laphumid
- Status last verified
- Mar 2014
- First submitted
- 17 Mar 2008
- Last updated
- 11 Mar 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Sammour T, Hill AG. Five year follow-up of a randomized controlled trial on warming and humidification of insufflation gas in laparoscopic colonic surgery--impact on small bowel obstruction and oncologic outcomes. Int Surg. 2015 Apr;100(4):608-16. doi: 10.9738/INTSURG-D-14-00210.1.
PubMed 25875541
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Humidification in Laparoscopic Colonic Surgery - A Double Blinded, Randomised Controlled Trial.
- ClinicalTrials.gov ID
- NCT00642005
- Acronym / sponsor ID
- Laphumid
- Conditions
- Peritoneal Inflammation
- Keywords
- Humidification, Laparoscopy, Colon, Hemicolectomy, Warming
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- University of Auckland, New ZealandUniversity, hospital or other
- Study start
- Apr 2008
- Primary completion
- Jun 2009 (actual)
- Study completion
- Aug 2009 (actual)
- First posted
- 24 Mar 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Laparoscopic surgery allows surgeons to remove bowel via small incisions. To allow insertion of a camera and instruments, cold and dry gas is blown into the abdominal cavity. This project investigates the use of warmed, humidified gas in laparoscopic surgery. The hypothesis is that this will result in less damage to internal surfaces, and shorten recovery time. Previous studies have demonstrated positive outcomes in laparoscopic gallbladder operations. The investigators plan to study patients undergoing laparoscopic colon operations, as these operations are longer and the effect of humidification will be magnified. The investigators will enroll 74 patients: 37 will have the operation with cold dry gas, and 37 will have warm, humidified gas. The investigators will measure intraoperative heat loss, postoperative pain, fatigue, nausea and vomiting, and time to return of bowel function.
Detailed description
The key determinants of a return to normal activity after major colorectal surgery are pain and fatigue. Our research group has an interest in enhancing perioperative care to reduce postoperative fatigue.
We have investigated the effect of peritoneal inflammation and the local production of cytokines on fatigue. Our data indicate that there is an association between the development of postoperative fatigue and the concentration of peritoneal cytokines following colorectal surgery. (Paddison, Hill - manuscript in submission). It is known that following surgery, there are two possible modes of communication between the cytokines and the brain. One is a hormonal routine by which the cytokines produced at the site of surgery enter the blood and proceed through cell surface receptors to act directly on the brain. The second method is a neural route represented by paracrine action of cytokines on primary afferent neurons that innervate the body site where the injury has taken place. In the abdominal cavity, the vagus nerve plays an important role in the latter form of communication. Vagal sensory neurons express large numbers of receptors for immune derived mediators, including a number of cytokines involved in inflammation and it has been shown that a major function of vagus may involve signaling immune and inflammatory situations. The vagus is unique as it has termination at the nucleus tractus solitarius (NTS) in the brain. The NTS is intensely activated following peripheral immune challenges and is also by far the most sensitive area in the brain following immune stimulation. The NTS projects monosynaptically to many regions of the brain which mediate sickness responses. Pro-inflammatory cytokines have been found in the blood, the skin, and the central nervous system after surgery and injury, however following major abdominal surgery such as colectomy these cytokines are found in very high concentrations in the peritoneal cavity. This local production of cytokines is far in excess of the amounts found in the serum suggesting an important local role and potentially a significant role in metabolic changes associated with colonic surgery. Therefore, inflammation and the consequent production of large concentrations of cytokines at the site of the surgery may activate the rich neurosensory vagal afferents to stimulate regions of the brain which mediate "sickness" responses. Therefore, it is feasible to hypothesize that strategies which lead to a reduction of the concentration of pro-inflammatory cytokines will lead to a reduction in post-operative fatigue.
In laparoscopic surgery, insufflated CO2 is delivered as defined by the United States Pharmacopoeia and National Formulary, which requires impurity of less than 200 parts per million, including water vapor. It is delivered at room temperature (21°C) with a relative humidity approaching 0%. Heat is lost by the body in warming and humidifying the cold, dry gas 1, and animal models have demonstrated that this can induce hypothermia. Initial human investigations showed that by simply heating the insufflating gas, core temperature was maintained and pain scores were improved. Additional findings showed heating and humidification helped to maintain core temperature in a porcine model 4. There is clinical evidence suggesting that heating and humidification can increase intraoperative core body temperature and reduce post-operative use of analgesia and pain scores for up to 14 days postoperatively. This intervention has also been linked significantly to an earlier return to normal activity in patients undergoing cholecystectomy.
Experimental studies have also shown that humidified gas is associated with less peritoneal and systemic inflammation compared to unhumidified gas. Furthermore, it has been demonstrated that use of warm, humidified gas is associated with a reduction in the concentration of peritoneal IL-6. The magnitude of this change is even larger than the effect seen after administration of anti-inflammatory agents in a similar setting. Significant reduction in other inflammatory peritoneal cytokines (TNF, IL-1) have also been observed in patients undergoing laparoscopic cholecystectomy with warmed CO2 insufflation gas.
Currently, there are no studies which have examined the effect of humidification in patients undergoing laparoscopic colonic surgery. We hypothesize that use of warm, humidified insufflation gas will lead to a reduction in hypothermia and concentration of peritoneal cytokines, with consequently decreased post-operative pain and fatigue, and earlier return to normal bowel function and activity. Our aim is to design and execute a double-blinded randomised controlled trial to test this hypothesis.
Research Design and Methods
Patients will be recruited from out-patient clinics across all three Auckland public hospitals. On the day of the operation, using opaque envelopes and computer generated random numbers; patients will be allocated into 2 groups. The intervention group will receive warm, humidified insufflation gas and control group will receive standard dry gas. Other intraoperative variables will be standardized and controlled. The patients, operating surgeons and other members of the clinical team will be blinded to the treatment given.
Using the data from a previous study measuring post-operative pain following colonic surgery; 37 patients are required in each group in to provide a 20% reduction in post-operative in hospital opiate use with alpha of 0.05 and power of 0.8. In order to achieve the required numbers we aim to enroll all patients undergoing laparoscopic colectomy from North Shore, Auckland and Middlemore Hospitals. Exclusion criteria:Patients under 15 years, acute cases, stoma formation (preop or intraop decision, decision to change to open surgery preoperatively (intraop conversions will be included as intention to treat), rectal lesions defined as less than 15cm from anal verge on imaging and/or sigmoidoscopy / colonoscopy, steroid dependence, inability to consent or answer SRS questions due to cognitive impairment or language barrier, ASA >= 4.
A reduction in postoperative morphine use forms the primary outcome of this study. Secondary outcomes include postoperative pain, fatigue, intraoperative heat loss and postoperative inflammatory response as measured by plasma and peritoneal pro-inflammatory cytokine concentration. Other outcomes that will be measured include nausea and vomiting, antiemetic use, and return of bowel function; with a reduction in these variables contributing to an endpoint of earlier return to normal activity.
Morphine equivalent analgesia usage will be documented in PACU, day of operation, day 1, day 2, and day 3. Visual analog scale measures of pain at rest will be obtained preoperatively, then at 2, 4, 8 and 12 hours, and days 1, 2, 3, 7, 14, 30, and 60 postoperatively.
Intraoperative temperature will be measured at 15min intervals using an naso-pharyngeal probe. A drain will be placed in the peritoneal cavity at the conclusion of surgery. On the morning following the operation, fluid from this drain as well as a simultaneous sample of blood will be collected, centrifuged and stored. Antioxidant levels will measures, and cytokine assays will be carried out by multiplexed cytometric bead immunoassays using the LINCOplex system (LINCO Research, St Charles, MO, USA). Drain fluid will be assayed for pro-inflammatory cytokines, IL-1a, TNF-a, IL-6, IL-8, IL-10 concentrations. Data will be acquired using a Luminex cytofluorimeter and analyzed using Luminex 100 IS software version 2.3 running a 4-parameter curve fit.
The SRS score will be used to measure surgical recovery, and will be administered preoperatively and also at days 1, 3, 7, 30, and 60. Anti-emetic use as well as time of return of normal bowel function (ability to eat and drink one complete hospital meal, passages of flatus or bowel motion and absence of nausea and vomiting) will also be recorded. Patients will be contacted on discharge to ascertain time to return of normal preoperative function.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Procedure: Fisher and Paykel Humidifier (MR860)Humidified and warmed carbon dioxide laparoscopic insufflation. |
| 2 | Placebo comparator | Procedure: Standard insufflationCold and dry carbon dioxide laparoscopic insufflation. |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- All patients 15 years and over undergoing elective laparoscopic colonic resection at all three auckland hospitals
Key exclusion criteria (7 listed)
- Acute cases
- Stoma formation (preop or intraop decision)
- Decision to change to open surgery preoperatively (intraop conversions included as intention to treat)
- Rectal lesions defined as 15 cm from anal verge on imaging and/or sigmoidoscopy / colonoscopy
- Steroid dependence
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fisher and Paykel Humidifier (MR860)Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation. | Procedure or surgery | 1 |
| Standard insufflationNo humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C. | Procedure or surgery | 2 |
Primary outcome
Pain by visual analogue scale
Time frame: preop, 2 hours, 4 hours, 8 hours, 12 hours, day 1, day 2, day 3, day 7, day 14, day 30, day 60
Morphine equivalent analgesia use
Time frame: PACU, day of OT, day 1, day 2, day 3, total in hospital
6 secondary outcomes
Intraoperative temperature by esophageal probe
Time frame: 15 min intervals during surgery
Plasma and peritoneal cytokine concentration
Time frame: Morning of surgery
Antiemetic use
Time frame: PACU, day of OT, day 1, day 2, day 3
Return of bowel function - passage of flatus, bm, and eating first meal
Time frame: daily
Any complications
Time frame: Up to 3 months postoperatively
Surgical recovery by SRS
Time frame: preop, day 1, day 2, day 3, day 7, day 30, day 60
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2014.
- Derived from this study: PubMed 25875541Sammour T, Hill AG. Five year follow-up of a randomized controlled trial on warming and humidification of insufflation gas in laparoscopic colonic surgery--impact on small bowel obstruction and oncologic outcomes. Int Surg. 2015 Apr;100(4):608-16. doi: 10.9738/INTSURG-D-14-00210.1.
Related trials for Peritoneal Inflammation
Active, not recruitingObservational study
Diet, Hepcidin, and Chemotherapy RDI
Breast Cancer Female, Ovarian Cancer
Recruiting
Vacuum Assisted Closure Versus On-demand Relaparotomy in Patients With Fecal or Diffuse Peritonitis
Fecal Peritonitis, Secondary Peritonitis
Not yet recruiting
Comparative Study Between Laparoscopic and Open Appendectomy of Complicated Appendicitis
Appendicitis, Perforated Appendicitis
Active, not recruitingPhase 4
Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis
Candidal Peritonitis
RecruitingObservational study
Peritoneal Dialysis Registration System (PERSIST)
ESRD, Disorders Associated With Peritoneal Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrew G Hill, MBChB, MD, FRACS study chair
University of Auckland, New Zealand
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fisher and Paykel Humidifier (MR860) and Standard insufflation in people with Peritoneal Inflammation, run by University of Auckland, New Zealand at 3 sites in New Zealand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain by visual analogue scale (time frame: preop, 2 hours, 4 hours, 8 hours, 12 hours, day 1, day 2, day 3, day 7, day 14, day 30, day 60). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00642005, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2014.